FFAR3 and inflammatory bowel disease: They exert beneficial effects on glucose and lipid metabolism and chronic inflammation through inhibition of histone deacetylation and/or binding to GPCRs such as GPR41, GPR43, and GPR109a [44], and reductions in their levels have been found to be associated with metabolic disorders or IBD [9].